Understanding systemic lupus erythematosus patients' desired outcomes and their perceptions of the risks and benefits of using corticosteroids
- PMID: 28857718
- PMCID: PMC5581720
- DOI: 10.1177/0961203317726375
Understanding systemic lupus erythematosus patients' desired outcomes and their perceptions of the risks and benefits of using corticosteroids
Abstract
Introduction The use of corticosteroids in systemic lupus erythematosus (SLE) patients requires difficult trade-offs between efficacy and risk of toxicity. This qualitative study examined SLE patients' most desired outcomes and their concerns with corticosteroid use in SLE treatment. Methods SLE patients with current/past experience with using corticosteroids were recruited from the clinics at the Johns Hopkins Lupus Center and the University of Maryland Medical Center. Five in-depth interviews ( N = 5) and four focus groups ( N = 15) were conducted during which discussions were transcribed and analyzed based on a grounded theory approach. Results We identified five major themes describing SLE patients' most desired outcomes: reduction in flares, maintenance of normal activities, minimization of treatment side effects, prevention of future organ damage, and finding a cure. Further, SLE patients reported these primary concerns with the adverse effects of corticosteroids: weight gain, organ damage (particularly bone-related damage), mood swings/irritability, sleep disturbances, and dental issues. Patients appeared to be more concerned with adverse effects that immediately affected their day-to-day lives. Conclusion Knowledge gained during this study better informs how patients view the benefits and risks of corticosteroids. This can facilitate discussions between physicians and patients as they work together to determine the appropriate use of corticosteroids.
Keywords: Corticosteroids; patients'; perceptions; systemic lupus erythematosus.
Similar articles
-
Anifrolumab treatment improves patient-reported quality of life and decreases disease activity and corticosteroid use in patients with systemic lupus erythematosus: A qualitative study in Denmark.Lupus. 2024 Aug;33(9):962-973. doi: 10.1177/09612033241261746. Epub 2024 Jun 20. Lupus. 2024. PMID: 38901042 Free PMC article.
-
Patients' Preferences for Systemic Lupus Erythematosus Treatments-A Discrete Choice Experiment.Patient. 2024 May;17(3):287-300. doi: 10.1007/s40271-023-00670-7. Epub 2024 Jan 25. Patient. 2024. PMID: 38270788
-
Weight loss and improvements in fatigue in systemic lupus erythematosus: a controlled trial of a low glycaemic index diet versus a calorie restricted diet in patients treated with corticosteroids.Lupus. 2012 May;21(6):649-55. doi: 10.1177/0961203312436854. Epub 2012 Feb 6. Lupus. 2012. PMID: 22311939 Clinical Trial.
-
Corticosteroid-associated lupus pancreatitis: a case series and systematic review of the literature.Lupus. 2019 May;28(6):731-739. doi: 10.1177/0961203319844004. Epub 2019 Apr 25. Lupus. 2019. PMID: 31023131
-
Current role of rituximab in systemic lupus erythematosus.Int J Rheum Dis. 2015 Feb;18(2):154-63. doi: 10.1111/1756-185X.12463. Epub 2014 Dec 19. Int J Rheum Dis. 2015. PMID: 25522652 Review.
Cited by
-
Patient Experiences of Systemic Lupus Erythematosus: Findings From a Systematic Review, Meta-Summary, and Meta-Synthesis.Arthritis Care Res (Hoboken). 2022 Nov;74(11):1813-1821. doi: 10.1002/acr.24639. Epub 2022 Jul 13. Arthritis Care Res (Hoboken). 2022. PMID: 34133081 Free PMC article.
-
The Burden of Glucocorticoids: Patterns of Use, Adverse Health Conditions, and Health Care Use in Two Cohorts With Systemic Lupus Erythematosus.ACR Open Rheumatol. 2024 Dec;6(12):918-926. doi: 10.1002/acr2.11733. Epub 2024 Oct 9. ACR Open Rheumatol. 2024. PMID: 39381836 Free PMC article.
-
Lifestyle Interventions and Weight Management in Systemic Lupus Erythematosus Patients: A Systematic Literature Review and Metanalysis.J Lifestyle Med. 2022 Jan 31;12(1):37-46. doi: 10.15280/jlm.2022.12.1.37. J Lifestyle Med. 2022. PMID: 35300036 Free PMC article.
-
Self-reported disease severity in women with systemic lupus erythematosus.Rheumatol Int. 2019 Mar;39(3):533-539. doi: 10.1007/s00296-018-4203-1. Epub 2018 Nov 10. Rheumatol Int. 2019. PMID: 30415452
-
Effectiveness and safety of telitacicept in patients with systemic lupus erythematosus: a single center, retrospective, real-world study.Clin Rheumatol. 2025 Mar;44(3):1113-1122. doi: 10.1007/s10067-025-07348-5. Epub 2025 Feb 4. Clin Rheumatol. 2025. PMID: 39903405
References
-
- Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003;30:1955–9. - PubMed
-
- McElhone K, Abbott J, Gray J, Williams A, Teh LS. Patient perspective of systemic lupus erythematosus in relation to health-related quality of life concepts: a qualitative study. Lupus. 2010;19:1640–7. - PubMed
-
- Boomsma MM, Bijl M, Stegeman CA, Kallenberg CG, Hoffman GS, Tervaert JW. Patients' perceptions of the effects of systemic lupus erythematosus on health, function, income, and interpersonal relationships: a comparison with Wegener's granulomatosis. Arthritis Rheum. 2002;47:196–201. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous